MAPT and Alzheimer disease: It has been shown that cutoffs with sensitivity set to 85% were defined in the AD control groups and tested in the MCI group, where the combination of Aβ42/p-tau ratio and t-tau identified incipient AD with a sensitivity of 83% (95% CI, 78%–88%) and specificity of 72% (95% CI, 68%–76%) [100].